Agevisa/PB Takes Action to Combat Smoking in Paraiba Region

Sep.01.2022
Agevisa/PB Takes Action to Combat Smoking in Paraiba Region
Brazil's Agevisa reinforces actions against smoking in Paraíba and emphasizes partnerships for health protection and environmental sustainability.

The Brazilian National Health Surveillance Agency (Agevisa) has been strengthening its actions and partnerships aimed at combating smoking in the Paraiba region throughout the year. On August 29th (National Day to Combat Tobacco), General Director Geraldo Moreira de Menezes outlined measures that not only aim to educate the public about the serious harm caused by tobacco products but also to train collaborating organizations to better protect human health and the state's environment.


He emphasized the importance of establishing partnerships between the State Health Surveillance Agency, Procon/PB, the Public Department, state and federal police, Sudema/PB, the Federal Revenue Service, and other state health agencies (members of this structure). This Agency has been providing advice on the implementation and execution of a quality management system for Agevisa/PB, which has yielded very positive results. The improvement of this Agency's activities in promoting and protecting human health in Paraíba has been positively impacted.


From August 22 to 25, Agevisa/PB actively participated in a training program on tobacco control legislation and inspection for health supervisors and Procons professionals in Paraiba. The event was held online and was co-organized by the National Cancer Institute (Inca), the National Health Surveillance Agency (Anvisa), and the Pan American Health Organization (PAHO).


Helena Teixeira de Lima Barbosa, the Technical Director of Agevisa/PB's Medical Science and Technology and Related department, discussed the role of health monitoring in tobacco control. She focused on the responsibilities and challenges facing regulators and highlighted the importance of societal awareness and participation in the fight against smoking. In her speech, Helena discussed Paraiba's health surveillance actions, responsibilities, legal documents, and experiences in combating smoking. She emphasized the extreme damage to health and the environment caused by the many substances in tobacco products, including electronic cigarette devices, also known as e-cigarettes.


According to Geraldo Moreira, this year Agevisa/PB has also promoted tobacco product inspection training for coordinators and municipal health inspectors to expand and improve the promotion and protection of public health in the region.


On June 14th and 15th, training was held for public health surveillance professionals in National Health Zones 1, 12, and 14. On March 30th, a training session was conducted for Visas staff from various cities in the second health zone during an event in Guarabira/PB.


Sustainability and tobacco control - Agevisa/PB is also actively involved in the National Cancer Institute's technical visit program to Paraiba to introduce sustainable tobacco control projects. From June 27th to July 1st, 2022, representatives from INCA, PAHO, the Secretary of State, and the Municipal Health Secretary discussed the project, Agevisa/PB, Empresa Paraibana de Turismo (PBTur), and tourism in the capital of Paraiba at the Casa de Jose Americo Foundation in João Pessoa/PB.


Geraldo Moreira de Menezes, the director general of Agevisa/PB, attended the event and emphasized the state government's commitment to expanding efforts to combat smoking in Paraiba. He discussed the agency's responsibility for oversight and education, and pointed out their concerns about the growth of smoking, including hookah and e-cigarettes.


Confiscation of electronic cigarettes - as part of a permanent effort to combat smoking in Paraiba, the director of Agevisa/PB emphasized on the 29th that the working group, which was launched on June 30th in João Pessoa/PB, seized a large number of electronic smoking devices at a tobacco store near Tambau. The owner of the establishment was arrested at the time and taken to the Federal Police Headquarters for questioning.


Késsia Liliana, the head of Procon/PB, Hugo José de Barros Franca, the health technology director, and Ado Augusto Bezerra de Brito, the health risk inspection and control technology manager from Agevisa attended this operation. PB, Procon inspectors, and federal police agent Geraldo Moreira announced an intensified inspection and imposed sanitary penalties on those responsible for public or private collective-use environments allowing the use of electronic cigarettes, vaporizers, vapes, and e-cigarettes throughout the state of Paraiba. The use of cigarettes, electronic cigarettes, e-cigarettes, or any other electronic smoking device (DEF) is prohibited in environments under their responsibility.


According to Geraldo Moreira, the initiative of Law 12,351/2022 aims to strengthen Paraiba's struggle against smoking by creating a smoke-free environment for collective use, considering whether Law 1 originated from smoke.


Disclaimer: 1. The content of this article is compiled from third-party information and is only for industry exchange and learning purposes. 2. This article does not represent the views of 2FIRSTS, and 2FIRSTS is also unable to confirm the truthfulness and accuracy of the content. The compile of this article is only for industry exchange and research purposes. 3. Due to the limited compilation level, the compiled article may not express the same meaning as the original, please refer to the original article for accuracy. 4. Regarding any domestic, Hong Kong, Macao, Taiwan, and foreign expressions and positions, 2FIRSTS maintains full consistency with the Chinese government. 5. The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us for deletion.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

FDA Appoints Former Tobacco Enforcement Deputy Jessica Zeller as Director as Agency Weighs PMTA Framework Changes
FDA Appoints Former Tobacco Enforcement Deputy Jessica Zeller as Director as Agency Weighs PMTA Framework Changes
The U.S. Food and Drug Administration (FDA) has named Jessica Zeller director of the Center for Tobacco Products' (CTP) Office of Compliance and Enforcement (OCE), effective November 1, 2026. Zeller, the office's inaugural deputy director, returns from medical device manufacturer Edwards Lifesciences with more than 20 years of regulatory and legal experience. The appointment follows CTP leadership changes and adjustments to tobacco regulation. Bret Koplow became permanent CTP director in September; the FDA revised enforcement priorities for unauthorized e-cigarettes and nicotine pouches in May and announced faster PMTA review procedures. On September 28, the agency said it would evaluate changes to the existing PMTA regulatory framework, including potential rulemaking to replace it.
FDA
Oct.20 by 2Firsts Perspectives
Why Does JPMorgan Favor BAT Over Philip Morris Despite Forecasting Slower Growth of 3.9% Versus 6.2%?
Why Does JPMorgan Favor BAT Over Philip Morris Despite Forecasting Slower Growth of 3.9% Versus 6.2%?
JPMorgan resumed equity research coverage of British American Tobacco (BAT), Philip Morris International (PMI) and Imperial Brands in November 2026, assigning BAT an Overweight rating and the other two companies Neutral ratings. The bank forecasts like-for-like sales growth of 3.9% for BAT and 6.2% for PMI in 2027, but estimates the two companies will trade at approximately 11 times and 21 times 2027 earnings, respectively. JPMorgan cited BAT's improving position in US nicotine pouches and vaping products as a driver of its investment outlook. BAT reported a 220% constant-currency increase in US modern oral nicotine revenue in the first half of 2026, while PMI's ZYN US shipments returned to growth in the third quarter. Imperial expects NGPs to represent 4% to 5% of sales and has expanded its oral portfolio through acquisitions.
Capital Markets
Nov.12
Beyond IQOS ILUMA, PMI Expands Lower-Priced BONDS Heated Tobacco Platform: Seven Markets Added in Q3, With Rollouts in Japan, Europe and North Africa
Beyond IQOS ILUMA, PMI Expands Lower-Priced BONDS Heated Tobacco Platform: Seven Markets Added in Q3, With Rollouts in Japan, Europe and North Africa
Philip Morris International (PMI) is expanding the international footprint of BONDS by IQOS, its lower-priced heated tobacco platform. The company's third-quarter 2026 SEC filing shows that BONDS devices and BLENDS tobacco sticks were available in 15 markets at the end of September, up from eight at the end of June. In November, PMI announced plans to extend sales from three to 17 Japanese prefectures and introduced BONDS in Spain and Morocco. The platform uses ROUNDHEAT external heating technology and proprietary tobacco sticks, separate from the IQOS ILUMA system. In Japan, BONDS retails for ¥2,980, approximately 25% below ILUMA i ONE, while BLENDS costs ¥570 per pack. PMI management says BONDS targets cigarette smokers who have not adopted heated tobacco. Separate sales and revenue figures remain undisclosed.
company
Nov.06
Iowa's First Vape Directory Lists JUUL and Vuse Pod Systems Alongside Loon and Crossbar Disposables, With 20,000-Puff Products Listed Across States
Iowa's First Vape Directory Lists JUUL and Vuse Pod Systems Alongside Loon and Crossbar Disposables, With 20,000-Puff Products Listed Across States
Iowa published its first vapor products directory on November 16, 2026, listing 361 product entries, including 175 covering prefilled pods, devices, kits and disposable e-cigarettes. Established tobacco-company brands such as JUUL and Vuse appear alongside independent disposable brands including Loon, Crossbar and Z Stick. The products range from traditional small-capacity disposables to Crossbar's 13mL, 20,000-puff devices. Of the 361 records, 288 are marked FDA Pending. Both Crossbar entries were dated November 16 and carry UPCs also found in other state directories. By contrast, a matching Z Stick product lost its active Louisiana listing after its certification was not renewed.
Regulations
Nov.17
Global Nicotine-Pouch E-Commerce Group Haypp Shuts Sweden’s Snusnetto Over Age Verification as Identity Checks Become Industry Infrastructure for New Nicotine Products
Global Nicotine-Pouch E-Commerce Group Haypp Shuts Sweden’s Snusnetto Over Age Verification as Identity Checks Become Industry Infrastructure for New Nicotine Products
Sweden's Supreme Administrative Court has declined to hear an appeal over age verification for tobacco and nicotine products collected from parcel lockers, leaving in place a lower-court ruling that geo-located BankID verification is insufficient to securely verify the actual recipient. Haypp Group has stopped tobacco and nicotine sales through Snusnetto and is deploying a new system across its other Swedish e-commerce sites to verify the age of the person who actually opens the locker and receives the shipment. The change comes as age verification across next-generation nicotine products expands from purchase checks into retail, delivery and, for some e-cigarettes, device access itself.
Regulations
Oct.20
Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia's Therapeutic Goods Administration published a final decision on September 25 to classify 6-methylnicotine as a Schedule 9 prohibited substance under the Poisons Standard, effective October 1, 2026. TGA said the chemical has been reported in e-cigarette liquids sold in Australia and marketed as nicotine-free or nicotine alternatives, while evidence also indicates its use in preparations such as oral pouches. The government originally proposed a Schedule 7 classification but ultimately adopted the stricter Schedule 9 designation, citing acute toxicity, dependence risk, use in unapproved consumer products and misleading marketing.
News
Sep.29 by 2Firsts Perspectives